Conduit Pharmaceuticals, Inc.

Conduit Pharmaceuticals (Nasdaq: CDT) have developed a unique business model to bring medicines to patients. Its novel approach addresses unmet medical need and lengthens the intellectual property for its existing assets through cutting-edge solid-form technology and then commercializes these products with life science companies. Conduit is led by a highly experienced team of pharmaceutical…More executives, including CEO, Dr. David Tapolczay, former Chief Executive Officer of UK-based medical research charity LifeArc; and the Chair of their Board, Dr. Freda Lewis-Hall, former Chief Medical Officer of Pfizer, Inc. Their Phase II ready pipeline, which consists of a HK4 Glucokinase Activator targeting auto-immune diseases and an MPO Inhibitor which they believe has the potential to treat Idiopathic Male Infertility, has undergone 20+ Phase I trials in over 1,000 patients.